Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis.

Clicks: 367
ID: 104393
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #14 of 39 articles by views in Journal of medical virology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Following the demonstration of efficacy of hydroxychloroquine against SARS-CoV-2 in-vitro, many trials started to evaluate its efficacy in clinical settings. However, no systematic review and meta-analysis has addressed the issue of safety and efficacy of hydroxychloroquine (HCQ) in COVID-19.We conducted a systematic review and metaanalysis with the objectives of evaluation of safety and efficacy of HCQ alone or in combination in terms of "time to clinical cure", "virological cure", "death or clinical worsening of disease", "radiological progression" and safety. RevMan was used for meta-analysis.We searched 16 literature databases out of which seven studies (n=1358) were included in the systematic review. In terms of clinical cure, 2 studies reported possible benefit in "time to body temperature normalization" and one study reported less "cough days" in the HCQ arm. Treatment with HCQ resulted in less number of cases showing radiological progression of lung disease (OR 0.31, 0.11-0.9). No difference was observed in virological cure (OR 2.37, 0.13-44.53), death or clinical worsening of disease (OR 1.37, 1.37-21.97) and safety (OR 2.19, 0.59-8.18), when compared to the control/conventional treatment. Five studies reported either the safety or efficacy of HCQ + Azithromycin. Although seems safe and effective, more data is required for a definitive conclusion.HCQ seems to be promising in terms of less number of cases with radiological progression with a comparable safety profile to control/conventional treatment. We need more data to come to a definite conclusion. This article is protected by copyright. All rights reserved.
Reference Key
sarma2020virologicaljournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sarma, Phulen;Kaur, Hardeep;Kumar, Harish;Mahendru, Dhruv;Avti, Pramod;Bhattacharyya, Anusuya;Prajapat, Manisha;Shekhar, Nishant;Kumar, Subodh;Singh, Rahul;Singh, Ashutosh;Dhibar, Deba Prasad;Prakash, Ajay;Medhi, Bikash;
Journal Journal of medical virology
Year 2020
DOI
10.1002/jmv.25898
URL
Keywords
meta-analysis hydroxychloroquine covid-19 2019-ncov sars cov-2

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.